2010NCCN指南-霍奇金淋巴瘤

Printed by tian meng on 7/31/2010 1:07:04 AM. For personal use only. Not approved for distribution. Copyright © 2010 National Comprehensive Cancer Network, Inc., All Rights Reserved.
These guidelines are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no representations nor warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. These guidelines are copyrighted by National Comprehensive Cancer Network. All rights reserved. These guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2010.
NCCN
®
Practice Guidelines in Oncology – v.2.2010
Hodgkin Lymphoma
Guidelines Index Hodgkin Lymphoma TOC Staging, Discussion, References
Table of Contents
NCCN Hodgkin Lymphoma Panel Members Summary of Guidelines Updates Diagnosis and Workup (HODG-1) Primary Treatment · Classical Hodgkin Lymphoma: CS IA-IIA Favorable (HODG-2) CS I-II Unfavorable (Bulky disease) (HODG-4) CS I-II Unfavorable (Non-bulky disease) (HODG-6) CS III-IV (HODG-8) · Lymphocyte-predominant Hodgkin Lymphoma: CS I-IV (HODG-10) Follow-up After Completion of Treatment and Monitoring For Late Effects (HODG-11) Relapse (HODG-12) Unfavorable Factors (localized and advanced disease) (HODG-A) Principles of Chemotherapy (HODG-B) Principles of Radiation Therapy (HODG-C) Revised Response Criteria (HODG-D) Principles of Second-line Chemotherapy (HODG-E) Guideline Index Print the Hodgkin Lymphoma Guidelines
Hodgkin Lymphoma
V.2.2010
Continue

Version 2.2010, 07/26/10 © 2010 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN.
NCCN
®
Practice Guidelines in Oncology – v.2.2010
Hodgkin Lymphoma
Guidelines Index Hodgkin Lymphoma TOC Staging, Discussion, References
NCCN Hodgkin Lymphoma Panel Members
Francisco J. Hernandez-Ilizaliturri, MD † Roswell Park Cancer Institute
Ephraim P. Hochberg, MD † Massachusetts General Hospital Cancer Center Melissa M. Hudson, MD ‡ St. Jude Children's Research Hospital/University of Tennessee Cancer Institute Mark S. Kaminski, MD † University of Michigan Comprehensive Cancer Center Gena Love ¥ New Mexico Department of Health Comprehensive Cancer Programs David G. Maloney, MD † ‡ Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
§ Radiation oncology † Medical Oncology ‡ Hematology/Hematology oncology x Bone Marrow Transplantation ¹ Pathology Þ Internal medicine ¥ Patient Advocacy * Writing Committee Member
* Richard T. Hoppe, MD/Chair § Stanford Comprehensive Cancer Center Ranjana Hira Advani, MD † Stanford Comprehensive Cancer Center Weiyun Z. Ai, MD ‡ UCSF Helen Diller Family Comprehensive Cancer Center Richard F. Ambinder, PhD, MD † The Sidney Kimmel Comprehensive Cancer Center at John Hopkins Philip J. Bierman, MD † ‡ x UNMC Eppley Cancer Center at The Nebraska Medical Center Kristie A. Blum, MD ‡ Arthur G. James Cancer Hospital & Richard J. Solove Research Institute at The Ohio State University Bouthaina Dabaja, MD § The University of Texas M. D. Anderson Cancer Center Benjamin Djulbegovic, MD, PhD † ‡ H. Lee Moffitt Cancer Center & Research Institute Andrew M. Evens, DO, MS ‡ Þ Robert H. Lurie Comprehensive Cancer Center of Northwestern University NCCN Guidelines Panel Disclosures Andres Forero, MD † ‡ University of Alabama at Birmingham Comprehensive Cancer Center Leo I. Gordon, MD ‡ Robert H. Lurie Comprehensive Cancer Center of Northwestern University David Mansur, MD Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine Peter M. Mauch, MD § Dana-Farber/Brigham and Women's Cancer Center Joseph O. Moore, MD † Duke Comprehensive Cancer Center David Morgan, MD † ‡ x Vanderbilt-Ingram Cancer Center Craig H. Moskowitz, MD † Þ Memorial Sloan-Kettering Cancer Center Russell J. Schilder, MD † ‡ Fox Chase Cancer Center Lawrence M. Weiss, MD ¹ City of Hope Jane N. Winter, MD ‡ Robert H. Lurie Comprehensive Cancer Center of Northwestern University Joachim Yahalom, MD § Memorial Sloan-Kettering Cancer Center
Continue
Version 2.2010, 07/26/10 © 2010 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission ofidelines in Oncology – v.2.2010
Hodgkin Lymphoma
Guidelines Index Hodgkin Lymphoma TOC Staging, Discussion, References
NCCN Clinical Practice Guidelines in Oncology™
Printed by tian meng on 7/31/2010 1:07:04 AM. For personal use only. Not approved for distribution. Copyright © 2010 National Comprehensive Cancer Network, Inc., All Rights Reserved.